Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC backs Babcock on strong marine outlook

(Sharecast News) - RBC Capital Markets has reiterated its 'outperform' rating on Babcock International Group, on the back of a strong outlook for the engineer's marine business. In a note published on Monday, RBC said that Babcock's recent marine investor day had "showcased that guidance is well underpinned, with upside potential, strengthening the conviction in our recent initiation".

"The event marked a narrative shift for shipbuilding to become a key earnings driver."

Guidance is currently for the marine division to reach sales of around £2bn at a 9% margin by the 2030 full year, which RBC said seemed "undemanding".

Babcock has a three-year shipbuilding pipeline of more than £16bn - significantly above RBC's initial £8bn estimate - which the broker noted was "further enhanced by a more than £1bn pipeline for advanced manufacturing".

RBC concluded: "We leave our estimates unchanged but increase our 2028 full-year estimated adjusted earnings per share upside scenario from pipeline opportunities to 9-37% (previously 8-30%). Near-term potential catalysts include contract wins at this week's DSEI conference, shipbuilding wins and the renewal of Future Maritime Support Programme."

Shares in Babcock were up 1% at 1,103p as at 1345 BST. RBC has a target price of 1,091p on the blue chip.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.